178 results about "Pathogenic Escherichia coli" patented technology

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E.Coli, Gemmiger, Desullomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. Coli, Gemmiger, Desulfamonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

The present invention relates to the use of F4+ non-pathogenic Escherichia coli strains to promote growth in an animal. The present invention also relates to the use of such strains to homogenize growth among a herd of animals. More specifically, the animal(s) of interest in the present invention are those wherein growth promotion or growth homogenization are desired goals, such as animals reared for meat production. The present invention further relates to a method for promoting growth of an animal as well as a method for homogenizing growth among a herd of animals.

The invention relates to a pathogenic microorganism DNA detection chip and the chip comprises a carrier and a nucleic acid probe on the carrier. The nucleic acid probe is provided with a target detection probe used for detecting target gene of pathogenic microorganism. The pathogenic microorganism comprises but not limits to vibrio cholerae, pathogenic escherichia coli, campylobacter jejuni, Yersinia enterocolitica, parahemolytic vibrio, salmonella, and shigella and Listeria monocytogenes. The invention also relates to a preparation method of the pathogenic microorganism DNA detection chip and provides applications of the pathogenic microorganism DNA detection chip in detection of pathogenic microorganism. Also a pathogenic microorganism DNA detection chip kit is provided.

The present invention relates to a method for the detection of pathogenic E. coli in a sample comprising PCR amplification of DNA isolated from said sample using oligonucleotide primers specific for pathogenic E. coli.

The invention discloses a feed compound enzyme-containing dedicated enzyme for growing pigs and a preparation method of the feed compound enzyme-containing dedicated enzyme, and belongs to the technical field of preparation of enzyme preparations. The dedicated enzyme for the growing pigs is prepared by scientifically compounding aspergillus niger cultures, acidic xylanase, phytase, beta-dextranase, cellulase, amylase, acid proteinase, Chinese herb extracts, a protective agent and an activating agent, wherein the aspergillus niger cells in the aspergillus niger cultures can inhibit the growth of pathogenic escherichia coli, inhibit the growth and breeding of aspergillus flavus, disintegrate the aspergillus flavus, promote the growth of animals, adjust gastrointestinal tract flora to be balanced, and enhance whole immunity during the processes of growth and fermentation, in addition, the fermentation liquid crude enzyme liquid of the aspergillus niger cultures contains different enzyme activity such as protease activity, mannase activity, alpha-galactase activity and pectinase activity, and the dedicated enzyme is specially suitable for being added in the feed for the growing pigs.

Disclosed herein are various polypeptides that can be included in immunogenic compositions specific for pathogenic E. coli strains. The polypeptides have cellular locations which render them accessible to the immune system. The genes encoding the polypeptides were initially identified as being present in uropathogenic strain 536 but absent from non-pathogenic strains.

The invention relates to a lactobacillus pentosus strain and a fermentation product of the same. The preservation number of the lactobacillus pentosus LPEM818 in the invention is CGMCC No. 4583 in the China General Microbiological Culture Collection Center. The fermentation product of the lactobacillus pentosus in the invention can inhibit common pathogenic escherichia coli, pseudomonas aeruginosa and staphylococcus aureus in food, and particularly has a strong inhibiting effect on listeria monocytogenes which can cause serious food poisoning. In addition, the metabolite of the strain also can inhibit the growth of aspergillus flavus and cotton and tomato blight pathogens. Consequently, the lactobacillus pentosus strain and the fermentation product thereof play an active role in the fields of food preservation and plant protection.

The invention discloses escherichia coli bacteriophage vB_EcoM_swi3 of which the preservation number is CCTCC M 2019467. The bacteriophage belongs to myoviridae, and is provided with a polyhedral headand a telescopic tail structure, wherein the diameter of the head is about 80nm, and the length of the tail is about 120nm. Bright plaque can be formed on a solid culture medium, an aureole does notexist on the periphery of the plaque, the edge is clear and regular, and the diameter is about 1-1.5mm. The bacteriophage has favorable splitting effects on pig-derived escherichia coli and chicken-derived escherichia coli, especially pig-derived pathogenic escherichia coli and chicken-derived pathogenic escherichia coli, and has quite great application prospects in a plurality of respects of medicinal preparations for preventing and treating pig-derived colibacillosis and chicken-derived colibacillosis, feed additives and the like.

The invention relates to a method for preparing lactoferrin antibacterial peptide through an enzyme method which belongs to the technical field for preparing the lactoferrin antibacterial peptide. The method of the invention comprises: taking lactoferrin as raw materials, adopting pig pepsin to hydrolyze the lactoferrin under certain condition, and finally obtaining lactoferrin antibacterial peptide mixture with stronger antibacterial activity. The method has simple process and strong practicability, the lactoferrin antibacterial peptide which is obtained has stronger antibacterial property and is broad-spectrum antibacterial peptide, gram-negative bacteria and gram-positive bacteria which contain pathogenic escherichia coli can be inhibited, eukaryotic cells are not affected, and the lactoferrin antibacterial peptide is functional antibacterial peptide and has better application prospect. The method for preparing the lactoferrin antibacterial peptide has important significance for promoting dairy products deep processing and colostrum resources comprehensive utilization, increasing health level of our people especially infants, and researching and developing functional food additives.

The invention provides a gene chip and a kit for detecting diarrheagenic escherichia coli in food and clinical samples. The gene chip comprises a solid-phase carrier and an oligonucleotide probe fixed on the solid-phase carrier, wherein the oligonucleotide probe contains DNA fragments and the complementary DNA or RNA sequence selected from eae genes of enteropathogenic escherichia coli (EPEC), lt, STap and STah genes of enterotoxigenic escherichia coli (ETEC), stx1 and stx2 of enterohaemorrhagic escherichia coli (EHEC), ipaH genes of enteroinvasive escherichia coli (EIEC), escherichia coli O157wzy genes and escherichia coli 16s genes. The invention further provides the kit containing the gene chip. The utilization of the gene chip and the kit for detecting the diarrheagenic escherichia coli has the advantages of simple operation, high accuracy and strong repeatability.

The invention belongs to the technical field of veterinary biology, and particularly relates to a colon bacillus outer membrane protein monoclonal antibody and a preparation method and an application thereof. The antibody is prepared by taking cloned, expressed and purified taking avian pathogenic escherichia coli 78 (APECO78) outer membrane protein as an antigen immune BALB / c mouse with a hybrid tumor technology. The antibody has high specificity and high sensitivity, and an experimental basis is laid for future rapid and specific detection of colon bacillus infection with an immunology method. Meanwhile, as proved by an experiment, the monoclonal antibody disclosed by the invention has high neutralizing activity and protecting efficiency on colon bacillus infection of the same type, and can be used for preventing colibacillosis.

The invention relates to a multi-PCR (polymerase chain reaction)-based method for quickly detecting four diarrhoeic Escherichia coli and special primers thereof. The method comprises the following steps: respectively selecting enterohemorrhagic Escherichia coli O157:H7O-antigen gene, enterotoxigenic Echerichia coli LT gene, enteropathogenic Echerichia coli bfpA gene and enteroinvasive Echerichia coli invasion plasmid gene as target genes, carrying out comparative analysis on the gene sequences, selecting the conserved region of the target gene sequence to design and synthesize the primers which are disclosed as SEQ ID NO.1-8 in the sequence table, and establishing a multi-PCR detection method to carry out qualitative detection on the four diarrhoeic Escherichia coli. The method provided by the invention has strong detection specificity. The invention also relates to a kit for detection. The invention is quick and simple and has the advantages of high accuracy and high sensitivity.

The invention discloses application of recombinant escherichia coli with overexpression of a fimH gene in the fermentation production of amino acid. According to the invention, by drawing lessons fromthe medical experience that compared with free cells, cells of a biological membrane formed by pathogenic escherichia coli are more adaptable to extreme environments, the formation of an escherichiacoli biological membrane can be regulated and controlled by the fimH gene regulated and controlled by a known fim operon, the change of an amino acid metabolic pathway after overexpression of the fimHgene is discovered through transcriptome analysis, groundwork is laid for screening recombination strains of other high-yield amino acid organic acid in a industrialization process in a later period,and the goal of increasing the yield, the fermentation rate and the sugar conversion rate is finally achieved.

The present invention relates to novel genes located in two chromosomal regions within uropathogenic E. coli that are associated with virulence. These chromosomal regions are known as pathogenicity islands (PAIs). In particular, the present application discloses 142 sequenced fragments (contigs) of DNA from two pools of cosmids covering pathogenicity islands PAI IV and PAI V located on the chromosome of the uropathogenic Escherichia coli J96. Further disclosed are 351 predicted protein-coding open reading frames within the sequenced fragments.

The invention provides a multiplex PCR (Polymerase Chain Reaction) primer group for avian pathogenic escherichia coli, pasteurella multocida, proteus mirabilis, pseudomonas aeruginosa, salmonella andstaphylococcus aureus, a multiplex PCR detection kit comprising the primer group, and a multiplex PCR detection method using the primer group. The primer group comprises primer pairs PhoA-F and PhoA-Rfor specifically amplifying a gene phoA of the avian escherichia coli, primer pairs KMT-F and KMT-R for specifically amplifying a gene KMT1 of the pasteurella multocida, primer pairs AtpD-F and AtpD-R for specifically amplifying a gene AtpD of the proteus mirabilis, primer pairs PETA-F and PETA-R for specifically amplifying a gene PETA of the pseudomonas aeruginosa, primer pairs InvA-F and InvA-Rfor specifically amplifying a gene InvA of the salmonella, and prier pairs NuC-F and NuC-R for specifically amplifying a gene nuc of the staphylococcus aureus.

The invention discloses an escherichia coli bacteriophage vBE_coM_swi3 with a preservation number of CCTCC NO: M2019467. The bacteriophage belongs to myoviridae and has a polyhedral head and a telescopic tail structure, the diameter of the head is about 80 nm, and the length of the tail is about 120 nm; transparent empty spots can be formed on a solid culture medium, no halo ring exists around thesolid culture medium, the edge is clear and regular, and the diameter is about 1-1.5 mm; the bacteriophage has a good cracking effect on swine-derived and chicken-derived escherichia coli in a breeding environment, particularly on swine-derived and chicken-derived pathogenic escherichia coli, and has very wide application prospects in multiple aspects of pharmaceutical preparations, feed additives and the like for preventing and treating swine colibacillosis and chicken colibacillosis.

The invention provides a method for wheat bran complex fermentation by utilizing a bacterium enzyme and belongs to the technical field of biological fermentation. According to the method, the following constituents are added into each gram of wheat bran: 2*109 endomycopsis yeast, 4*109 bacillus subtilis, 5*109 lactic acid bacteria, 10 U Alpha-amylase and 10 U phytase; the material-to-water ratio is regulated between 1:0.7 and 1:1; sealing fermentation is carried out at 30-50 DEG C for 48 h. The method is simple in process and low in cost, and has the advantages that solid fermentation is adopted; the final product needs not to be dried so as to avoid microorganism disruption; neither phytic acid nor mycotoxin is detected after fermentation; meanwhile, the fermented wheat bran is rich in a variety of probiotics and metabolites thereof, so that the growth and reproduction of harmful germs such as pathogenic escherichia coli and salmonella can be effectively restrained, and the animal immunity can be improved.

The invention discloses a special enzyme containing a feed composite enzyme for piglets and a preparation method thereof, belonging to the technical field of preparation of enzyme preparations. The special enzyme for piglets is prepared by scientifically compounding Aspergillus niger culture, acidic xylanase, cellulase, beta-glucanase, amylase, phytase, Chinese herbal medicine extract, a protective agent and an activator, wherein Aspergillus niger body in the Aspergillus niger culture can inhibit the growth of pathogenic escherichia coli in processes of growth and fermentation, inhibit the growth and reproduction of Aspergillus niger, decompose aflatoxin, promote animal growth, regulate flora balance in gastrointestinal tract, and improve overall immunity; the crude enzyme liquid of fermentation liquor of the Aspergillus niger culture contains activity of multiple enzymes such as protease, mannase, alpha-galactase and pectinase, thus being especially suitable for being added into feed for piglets.

The invention discloses Bacillus pumilus JY2 with the preservation number of CGMCC NO. 9150. The Bacillus pumilus JY2 is sampled from a winter wheat field (N 72 degrees 50 minutes 70.01 seconds E40 degrees 26 minutes 51.73 seconds) in an Osh race course of Kyrgyz Republic and is subjected to separating, screening and physiological and biochemical identification. The Bacillus pumilus JY2 with the preservation number of CGMCC NO. 9150, provided by the invention, has a good application effect on inhibiting pathogenic escherichia coli and salmonella, has a remarkable technical effect on applications in feeding microbioecologics and has broad application prospect in feed additive industries.

The invention provides a pediococcus pentosaceus NHB-PpA9601. The pediococcus pentosaceus NHB-PpA9601 is separated from intestinal tracts of white feather broilers, and is preserved in China General Microbiological Culture Collection Center (CGMCC for short, the address is Institute of Microbiology, Chinese Academy of Sciences, 3 #, 1 # yard, West Beichen Road, Chaoyang District, Beijing, the postal code is 100101), the preservation number is CGMCC NO.22646, and the preservation date is May 31, 2021. The pediococcus pentosaceus NHB-PpA9601 has the advantages that the obvious probiotic property is realized, the growth and reproduction of pathogenic bacteria such as intestinal pathogenic escherichia coli, staphylococcus aureus, salmonella suis, salmonella choleraesuis, salmonella gallinarum, salmonella pullorum, salmonella typhimurium, salmonella, shigella, bacillus perfringens, proteus penneri, aeromonas hydrophila and vibrio parahaemolyticus can be effectively inhibited; the pediococcus pentosaceus NHB-PpA9601 can be used for producing a wet-based fermented feed, and can be used for effectively improving intestinal health and increasing economic benefits.

The present invention relates to the use of F4+ non-pathogenic Escherichia coli strains to promote growth in an animal. The present invention also relates to the use of such strains to homogenize growth among a herd of animals. More specifically, the animal(s) of interest in the present invention are those wherein growth promotion or growth homogenization are desired goals, such as animals reared for meat production. The present invention further relates to a method for promoting growth of an animal as well as a method for homogenizing growth among a herd of animals.

The invention provides a method, a gene chip and a detection reagent kit for detecting common cow pathogenic escherichia coli. The gene chip comprises a solid phase carrier and an oligonucleotide probe fixed on the solid phase carrier, wherein the oligonucleotide probe comprises DNA (Deoxyribonucleic Acid) fragments selected from a glycosyl transferase gene and an oligose unit processing enzyme gene on a main escherichia coli serotype O-antigen gene cluster relative to cow septicemia and diarrhea. The gene chip and a designed primer are utilized for detecting and can be prepared into the reagent kit. The products and the method of the invention are utilized to reach the purpose for detecting the serotype of the common cow pathogenic escherichia coli and have the advantages of simple and convenient operation, high throughput, high accuracy, strong repeatability and important significance on the research and the diagnosis of epidemiology.

The invention provides a traditional Chinese medicine composition for treating porcine pathogenic Escherichia coli diseases. The raw material medicines comprise common andrographis herb, scutellaria baicalensis, white paeony root, cacumen biotae, hempleaf negundo chastetree leaf, the root of Chinese pulsatilla, codonopsis pilosula, radix bupleuri, madder, smoked plum, centipeda minima, hawthorn, pericarpium citri reticulatae, rhizoma polygonati, rhizoma kaempferiae, honeysuckle stem, rhizoma galangae, adenophora tetraphylla, gorgon fruit, corydalis tuber, folium ginkgo, fringed pink and semen raphani. The traditional Chinese medicine composition provided in the invention has the advantages of bacteria resistance, virus resistance, small side effects, zero residue and no drug resistance, is a good substitute of antibiotics and has a wide development prospect in the aspect of treating the porcine pathogenic Escherichia coli diseases.

The invention relates to the field of microecological feed additives, and particularly relates to preparation and application of a composite microecological feed additive. The composite microecological feed additive provided by the invention is prepared from screened active compound probiotics. Diarrhea caused by domestic animal bacterial infections can be prevented and treated. Two probiotics used by the composite microecological feed additive have the abilities of inhibiting infection of common gastrointestinal pathogens of animals, including shigella dysenteriae, pathogenic escherichia coli and salmonella enteritidis, and also can reduce the toxicity caused by dysentery bacillus infection Caco-2 cells and inhibit adhesion of the shigella dysenteriae to the Caco-2 cells. Finally, the obvious effects of stimulating the animal immunity, improving the gastrointestinal digestion abilities of animals, and promoting animal growth are achieved. A production technology of a strain adopts a liquid fermental cultivation technology and a low-temperature freeze drying technology, so that the obtained inoculant is high in survival rate and purity. The composite microecological feed additive is a green environment-friendly feed additive.

The invention belongs to the technical field of microorganism application, and relates to probiotic clostridium butyricum and application thereof. The clostridium butyricum is separated from fresh chicken manure of an autotrophic chicken farm, and has a remarkable inhibiting effect on pathogenic escherichia coli and clostridium perfringens of cultured animals. After the clostridium butyricum is subjected to anaerobic fermentation culture, a liquid microbial agent product can be prepared for the cultured animals to drink to achieve a probiotic effect. A fermented bacterial solution can be further dried and processed to prepare viable bacterial powder, and the viable bacterial powder is added into livestock and poultry feed as a solid microbial agent to feed the animals. The probiotic clostridium butyricum is applied to livestock and poultry breeding, the health condition of the cultured animals is effectively improved, the production performance is improved, the occurrence rate of enteritis and diarrhea of the livestock and poultry is reduced, the use of antibiotics is reduced, and support is provided for green breeding in the livestock and poultry industry.

The invention belongs to the veterinary biotechnical field, in particular to a riemerella anatipestifer-escherichia coli outer membrane protein bivalent vaccine and a preparation method thereof. The riemerella anatipestifer-escherichia coli outer membrane protein bivalent vaccine is prepared by emulsifying an antigen and oil adjuvant according to the volume ratio of 1:1-1:5, wherein the antigen is a riemerella anatipestifer RA1 outer membrane protein and / or a riemerella anatipestifer RA2 outer membrane protein and an avian pathogenic escherichia coli 078 outer membrane protein. As proved by an animal experiment, a vaccine immune animal prepared by adopting the method has high vaccine safety and a remarkable immune effect, a high-titer antibody can be generated inside the animal, and the attack of the same type of riemerella anatipestifer and a plurality of serum escherichia coli can be resisted.

The invention discloses an RPA-LFD primer pair and probe for detecting pathogenic escherichia coli O157:H7 and application thereof. As for the sequences of the primer pair and the probe, the nucleotide sequence of an upstream primer EOF4 is SEQ ID NO.6; the nucleotide sequence of a downstream primer EOR3 is SEQ ID NO.7; the nucleotide sequence of the probe EOProb is SEQ ID NO.9. By means of a method, the defects of existing detection technologies are overcome through safe, specific, rapid, sensitive and simple on-site detection. It is proved through experiments that the minimum reaction volumeof an RPA-LFD technology is 10 microliters, the optimum reaction temperature is 40 DEG C, the shortest detection time is 15 min, the reaction cost is greatly saved, and the time required for detection is shortened. The optimum primers screened by the RPA reaction are high in specificity and sensitivity, and the sensitivity of RPA-LFD is 100 times that of PCR.

The invention belongs to the technical field of biology and relates to a preparation method and application of a novel antimicrobial peptide Misgurin mutant. The technical scheme is as follows: introducing glutamine at the C tail end of the amino acid sequence of natural Misgurin so as to design a novel Misgurin mutant; selecting Pichia yeast biased codons so as to artificially synthesize a complete gene of the novel Misgurin mutant; constructing a Pichia yeast secretion type expression vector pPICZaA-M; transforming a host cell SMD1168 by a vector electroporation method; selecting to obtain high-efficiency expression strains; and under proper culture conditions, ensuring 100 microgram of recombinant novel Misgurin mutant is contained in per milliliter of expression supernatant. The obtained product has a good nematocidal activity on staphylococcus aureus, pig salmonella and pig pathogenic Escherichia coli K88, K99 and 987P, and has an obvious effect on prevention and treatment of clinical bacterial diseases.

The present invention provides a polypeptide, called EspA, which is secreted by pathogenic E. coli, such as the enteropathogenic (SPEC) and enterohemorrhagic (EHEC) E. coli. The invention also provides isolated nucleic acid sequences encoding EspA polypeptide, EspA peptides, a recombinant method for producing recombinant EspA, antibodies which bind to EspA, and a kit for the detection of EspA-producing E. coli.